| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-05-26 | caplacizumab | thrombotic thrombocytopenic purpura | 2 | Ablynx (Belgium) | Autoimmune diseases - Rare diseases |
| 2016-05-25 | grass allergy immunotherapy | grass allergy | 3 | Circassia Pharmaceuticals (USA) | Allergic diseases |
| 2016-05-25 | ALKS 4230 (RDB 1450) and Keytruda® (pembrolizumab) | advanced solid tumors | 1 | Alkermes (Ireland) | Cancer - Oncology |
| 2016-05-25 | solithromycin | mild to moderate community-acquired pneumonia (CABP) | 2 | Cempra (USA - NC) Toyama Chemical (Japan) | Infectious diseases |
| 2016-05-25 | BAX 930/SHP655 | hereditary thrombotic thrombocytopenic purpura | 1 | Baxalta (USA - IL), now Shire (UK - USA) | Autoimmune diseases - Rare diseases |
| 2016-05-25 | Ovasave® (antigen-specific type 1 regulatory T (Ag-Treg) cell based immunotherapy) | Crohn disease | 2b | TxCell (France) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2016-05-24 | BI 655066/ABBV-066 (risankizumab) | Crohn disease | 2 | Abbvie (USA - IL) Boehringer Ingelheim (Germany) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2016-05-23 | talazoparib | advanced breast cancer | 2 | QuantumLeap Healthcare Collaborative (USA - CA) Medivation (USA - CA) | Cancer - Oncology |
| 2016-05-20 | JNJ-61178104 | 1 | Janssen Research & Development, a J&J company (USA - NJ) | ||
| 2016-05-20 | lurbinectedin (PM1183) in combination with irinotecan | advanced solid tumors | 1 | PharmaMar (Spain) | Cancer - Oncology |
| 2016-05-20 | afatinib | advanced/metastatic urothelial tract carcinoma | 2 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2016-05-19 | MM-151 in combination with Onivyde® (irinotecan liposome injection) plus fluorouracil and leucovorin | RAS wild-type metastatic colorectal cancer (mCRC) | 1 | Merrimack Pharmaceuticals (USA - MA) Baxalta (USA - IL) | Cancer - Oncology |
| 2016-05-19 | talimogene laherparepvec | breast cancer | 1-2 | Amgen (USA - CA) | Cancer - Oncology |
| 2016-05-19 | combination regimens including MM-151, istiratumab (MM-141), seribantumab (MM-121) selected using a combination of genetic and nongenetic biomarkers | colorectal cancer, non-small cell lung cancer, squamous cell carcinoma of the head and neck | 1 | Merrimack Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2016-05-19 | Aplidin® (plitidepsin) in combination with bortezomib and dexamethasone | relapsed and/or refractory multiple myeloma | 1 | PharmaMar (Spain) | Cancer - Oncology |
| 2016-05-18 | XmAb®7195 | 1a | Xencor (USA - CA) | Allergic diseases - Inflammatory diseases - Respiratory diseases | |
| 2016-05-18 | Lymfactin® | breast cancer associated secondary lymphedema | 1 | Herantis Pharma (Finland) | Cancer - Oncology |
| 2016-05-18 | SYD985 (HER2-targeting antibody-drug conjugate based on trastuzumab and Synthon’s proprietary cleavable linker-duocarmycin (vc-seco-DUBA) payload) | locally advanced or metastatic solid tumors including breast cancer, gastric cancer | 1 | Synthon (The Netherlands) | Cancer - Oncology |
| 2016-05-18 | PBI-4050 | cystic fibrosis-related diabetes | 2 | ProMetic Life Sciences (Canada) | Fibrotic diseases - Metabolic diseases |
| 2016-05-18 | ANAVEX2-73 (tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride) | infantile spasms | preclinical | Anavex Life Sciences (USA - NY) | CNS diseases |
